Skip to main content
. 2021 Jul 3;38(4):330–337. doi: 10.4103/lungindia.lungindia_118_19

Table 6.

Distribution of adverse drug reactions experienced after the start of therapy

Frequency, n (%)

After 6 months of therapy After 12 months of therapy After 24 months of therapy
Gastrointestinal symptoms
 Nausea and vomiting 20 (30.76) 57 (39.86) 6 (21.42)
 Severe gastritis 8 (12.30) 6 (4.19) 5 (17.85)
Musculoskeletal disorders
 Arthralgia 3 (4.61) 25 (17.48) 5 (17.85)
Skin and subcutaneous tissue disorders
 Acne vulgaris 4 (6.15) 7 (4.89) 2 (7.14)
 Dermatitis 3 (4.61) 4 (2.79) 0
Central nervous systems disorders
 Peripheral neuropathy 5 (7.69) 13 (9.09) 3 (10.71)
 Giddiness 7 (10.76) 14 (9.79) 0
Endocrine disorders
 Hypothyroidism 4 (6.15) 3 (2.09) 0
 Gynaecomastia 2 (3.07) 1 (0.69) 0
Psychiatric disorders
 Psychosis 2 (3.07) 2 (1.39) 0
Renal toxicity
 Nephrotoxicity 0 3 (2.09) 0
Vestibular toxicities
 Ototoxicity 0 3 (2.09) 3 (10.71)
 Tinnitus and mild hearing loss 7 (10.76) 5 (3.49) 4 (14.28)
Total (n) 65 143 28

ADRs: Adverse drug reaction